Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Tinib Antineoplastic drugs >  Bosutinib

Bosutinib

Basic information Safety Related Supplier
Bosutinib Basic information
Bosutinib Chemical Properties
  • Melting point:116-120 ºC
  • Boiling point:649.7±55.0 °C(Predicted)
  • Density 1.36
  • storage temp. room temp
  • solubility DMSO: ≥15mg/mL
  • pka7.63±0.10(Predicted)
  • form powder
  • color off-white to light brown
  • InChIKeyPICKMQXYAMDEPF-UHFFFAOYSA-N
  • CAS DataBase Reference380843-75-4(CAS DataBase Reference)
Safety Information
  • Hazard Codes Xi
  • Risk Statements 36
  • Safety Statements 26
  • WGK Germany 3
  • HS Code 29335990
Bosutinib Usage And Synthesis
  • DescriptionIn September 2012, the US FDA approved bosutinib (also referred to as SKI-607) for the treatment of relapsed or refractory chronicmyeloid leukemia (CML) for patients with resistance or intolerance to prior therapy. The National Cancer Institute estimates that in 2012, 5430 men and women were diagnosed with CML and 610 died of CML. First and second-line therapies for the treatment of CML include imatinib, dasatinib, and nilotinib. Bosutinib, which was initially identified as a Src inhibitor, was later found to be a dual inhibitor of Bcr–Abl (IC50=1.4 nM) and Src family kinases (IC50=3.5 nM). Bosutinib inhibits 16 of 18 imatinib-resistant forms of Bcr–Abl expressed in murine myeloid cell lines. In preclinical in vivo studies, bosutinib at 15 mg/kg administered orally for 5 days caused regression of K562 CML tumors in nude mice and in BaF3 tumors expressing wild type or different imatinib-resistant Bcr–Abl mutants at varying doses. A manufacturing process for the synthesis of bosutinib monohydrate has been reported that employs a key three-component cyclization reaction involving an aniline, a cyanoacetamide intermediate, and triethyl orthoformate followed by cyclization using phosphorous oxytrichloride and an optimized hydration procedure.
  • Chemical PropertiesPale Yellow Solid
  • OriginatorWyeth (United States)
  • UsesBosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
  • UsesA novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
  • Usesperipheral vasolidator increases cerebral blood flow, potential therapeutic for Altzheimer’s disease, cognitive impairment and dementia
  • DefinitionChEBI: An aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively.
  • brand nameBosulif
Bosutinib(380843-75-4)Related Product Information
BosutinibSupplierMore
  • Company Name:Shanghai Kuanghao Chemistry Technology Co., Ltd. Gold
  • Tel:15900820856 021-37285271
  • Email:wyzh0916@hotmail.com
  •  
  • Company Name:Shanghai TaoShu Biochemical Technology Co., Ltd. Gold
  • Tel:15002134094 021-33632979-
  • Email:service1@targetmol.com
  •  
  • Company Name:Hengyang Jiaxuan Biotechnology Co. LTD Gold
  • Tel:18684598761
  • Email:675042965@qq.com
  •  
  • Company Name:Chongqing Yuzhiquan Biological Technology Co., Ltd. Gold
  • Tel:18306022109 023-18306022-109
  • Email:2966918840@qq.com;2910278169@qq.com;2974174958@qq.com;
  •  
  • Company Name:Yunfei Pharmaceutical(Shenzhen) Co., Ltd. Gold
  • Tel:15994832653
  • Email:hulixiu@yunfeipharma.com;
  •